Cloud Compliance FAQs for Biotech & Pharma

GxP (Good Practice guidelines) in the cloud refers to ensuring that cloud infrastructure used in pharmaceutical or biotechnology processes meets the validation, documentation, and control requirements of GxP regulations — including GMP, GLP, GCP, and GDP. AWS cloud environments can be configured and validated to meet GxP requirements, including access controls, audit trails, change management, and data integrity. skyPurple Cloud specialises in this validation process.

Computer System Validation (CSV) is a documented process demonstrating that a computer system consistently produces results meeting its intended use and regulatory requirements. Yes — any cloud system used in a GxP process (e.g., LIMS, ELN, MES, or a cloud platform hosting GxP data) requires validation. This includes producing Installation Qualification (IQ), Operational Qualification (OQ), and Performance Qualification (PQ) documentation.

Annex 11 is a European GMP guideline governing computerised systems used in pharmaceutical manufacturing. It covers the entire lifecycle of a computerised system from validation through decommissioning. For cloud systems, Annex 11 requires: supplier assessment of the cloud provider (e.g., AWS), data integrity controls, audit trails, access management, backup and recovery, and change control. AWS has published a GMP Annex 11 whitepaper to assist pharma companies.

21 CFR Part 11 is a US FDA regulation governing electronic records and electronic signatures. For cloud systems, it requires: unique user IDs and passwords for all system access, audit trails capturing who changed what and when, system-generated time-stamps, controls preventing backdating or modification of records, and validated performance. Any SaaS or cloud-hosted application used to store FDA-regulated electronic records must meet Part 11 requirements.

Data integrity in GxP refers to the completeness, consistency, and accuracy of data throughout its lifecycle, governed by ALCOA+ principles: Attributable, Legible, Contemporaneous, Original, Accurate, Complete, Consistent, Enduring, and Available. Data integrity failures are one of the leading causes of FDA warning letters and MHRA deficiency findings. In cloud environments, data integrity requires immutable audit logs, encryption, backup validation, and access controls.

Yes. AWS is used by hundreds of pharmaceutical and biotech companies for GxP-regulated workloads including LIMS, ELN platforms, clinical data management, and manufacturing execution systems. AWS has published GxP whitepapers and maintains a compliance centre documenting its controls. However, using AWS for GxP does not eliminate the customer's responsibility to validate the AWS environment as used — the customer must perform and document their own qualification activities.

HIPAA (Health Insurance Portability and Accountability Act) requires organisations handling Protected Health Information (PHI) to implement specific technical, physical, and administrative safeguards. In a cloud context: all PHI must be encrypted at rest and in transit; access must be controlled with least-privilege principles; audit logs must be maintained; a Business Associate Agreement (BAA) must be signed with your cloud provider. AWS is HIPAA-eligible and provides a BAA.

A Business Associate Agreement (BAA) is a contract required under HIPAA between a covered entity (e.g., a healthcare provider) and any business associate (e.g., cloud provider) that may access PHI on their behalf. If you are processing, storing, or transmitting PHI using AWS, you must sign a BAA with AWS. AWS offers a standard BAA covering eligible HIPAA services (not all AWS services are HIPAA-eligible — check the AWS HIPAA-eligible services list).

GDPR (General Data Protection Regulation) governs the processing of personal data of EU individuals and has significant implications for life sciences companies handling clinical trial participant data, patient records, or employee data. Key cloud requirements: data must be processed on the basis of a lawful legal ground; data subjects have rights of access and erasure; data transfers outside the EU require appropriate safeguards (Standard Contractual Clauses or adequacy decisions); and appropriate technical measures (encryption, access controls) must be in place.

For global life sciences companies, HIPAA applies to US patient data (PHI) while GDPR applies to EU personal data — including EU clinical trial participants, employees, and customers. Requirements overlap significantly: both demand encryption, access controls, audit trails, and documented data processing activities. However, GDPR's data subject rights (erasure, portability) and lawful basis requirements go beyond HIPAA. Most compliant cloud architectures can satisfy both frameworks simultaneously with careful data residency and processing design.

The AWS Shared Responsibility Model divides security responsibilities between AWS and the customer. AWS secures the physical infrastructure, hypervisor, and managed service components ('security of the cloud'). The customer is responsible for operating systems, applications, data, and access controls ('security in the cloud'). Life sciences organisations often underestimate their obligations — particularly around patch management, access controls, encryption key management, and network configuration.

Commonly used AWS services in validated life sciences environments include: Amazon EC2 and EKS for compute; Amazon RDS and Aurora for validated databases; Amazon S3 with Object Lock for immutable data storage; AWS CloudTrail for audit logging; AWS Identity and Access Management (IAM) for access controls; AWS KMS for encryption key management; and Amazon VPC for network isolation. Each of these has been used in GxP-validated and HIPAA-compliant deployments.

Access controls in regulated cloud environments should follow least-privilege principles: each user and system should have only the minimum permissions required for their function. Best practices include: multi-factor authentication (MFA) for all human users; role-based access control (RBAC) using AWS IAM roles; no shared accounts or generic logins; automated deprovisioning when employees leave; periodic access reviews; and privileged access management (PAM) for administrative accounts. All access events should be logged via AWS CloudTrail.

Encryption at rest protects stored data from unauthorised physical access (e.g., using AWS KMS with AES-256). Encryption in transit protects data moving between systems (e.g., TLS 1.2+). Both are required under HIPAA, strongly recommended under GxP guidance, and mandated by ISO 27001 and SOC 2. In practice, all regulated data in cloud environments should be encrypted at both states, with encryption keys managed through a formal key management process.

A Virtual Private Cloud (VPC) is a logically isolated section of the AWS cloud with its own network configuration. VPCs are fundamental to regulated cloud architecture: they allow you to control which systems can communicate with each other and with the internet, enforce network segmentation between production and development environments, and implement defence-in-depth security. All GxP and HIPAA-regulated workloads should run within dedicated, appropriately configured VPCs.

FinOps (Financial Operations) is a cloud financial management framework that brings engineering, finance, and operations teams together to make data-driven spending decisions. In life sciences, cloud costs can spike significantly during compute-intensive phases — drug discovery ML workloads, genomics processing, or clinical trial data analysis. FinOps discipline ensures these costs are visible, controlled, and optimised without constraining research or violating change control requirements.

Reserved Instances (RIs) and Savings Plans are AWS commitment-based pricing models offering discounts of 30–72% in exchange for 1 or 3-year usage commitments. RIs are specific to instance families and regions; Savings Plans offer more flexibility. Best suited for predictable, stable workloads (LIMS, ELN, databases). For variable research compute, Spot Instances or On-Demand pricing may be more appropriate. A FinOps strategy typically combines all three.

Cost optimisation in regulated environments requires a validation-aware approach. All infrastructure changes — even cost-saving modifications like resizing instances — must be documented, go through change control where required, and be tested in non-production environments first. skyPurple follows this approach: generating change control documentation, preserving audit trails, and ensuring optimisation activities do not invalidate previously validated configurations.

Yes, but traditional DevOps must be adapted for GxP. 'Validated DevOps' or 'GxP DevOps' incorporates automated testing as validation evidence, formalised pipeline qualification, documented change control, and audit trails for every deployment. The key is that the CI/CD pipeline itself must be validated, and every deployment must produce evidence that satisfies regulatory requirements — including test results, review records, and approval signatures.

GxP-compliant AI means that AI/ML systems used in regulated processes (drug development, manufacturing, clinical decision support) are validated, auditable, and controlled under change management. Requirements include: model versioning and provenance tracking; documented training data and methodology; validation testing before production deployment; ongoing monitoring for model drift; and change control for model updates. The FDA's 2021 AI/ML Action Plan provides guidance for SaMD (Software as a Medical Device).

In regulated environments, the choice between IaaS, PaaS, and SaaS affects your validation responsibilities. With IaaS (e.g., AWS EC2), you control and must validate everything above the hypervisor. With PaaS (e.g., AWS Elastic Beanstalk), the provider manages more of the stack, reducing but not eliminating your validation scope. With SaaS (e.g., Veeva Vault), the provider supplies most validation documentation, but you must still qualify the system for your intended use and conduct user acceptance testing.

They apply to different things, and both can apply at once. GxP governs whether a system is fit for its regulated purpose and validated; the EU AI Act governs the AI itself by risk tier. A GxP-validated AI tool may still owe transparency duties or, for clinical uses, high-risk obligations. In practice, the validation evidence produced for GxP covers much of what the AI Act expects, but risk classification and any AI-specific duties must be addressed separately.

You validate the system around the model, not every individual output. Define the intended use and acceptance criteria, fix and version the model and prompt set, test against a representative question set with expected answers and refusal cases, and monitor for drift in production. Because LLMs are non-deterministic, validation relies on documented guardrails, human review where outputs affect decisions, and reproducible evidence of how the system behaves.

Log every action an agent takes, not just its conversation. Each tool call, query, parameter and result is recorded with a timestamp and the identity that authorised it, so the sequence can be replayed and reviewed. Guardrails restrict what the agent may touch, and sensitive actions require human approval. That log becomes the audit trail showing exactly what the AI did and why.

Yes, with human authorship and review. AI can draft and assemble validation documentation from source material, which saves significant time, but a qualified person must review, correct and approve each document. The output is treated as a draft produced under governed prompts, and the review record — who checked what and when — is retained. AI accelerates the drafting; accountability for the content stays with your team.